We are live on ! Find out more
CLDX icon

Celldex Therapeutics
CLDX

228 hedge funds and large institutions have $2.31B invested in Celldex Therapeutics in 2026 Q1 according to their latest regulatory filings, with 60 funds opening new positions, 67 increasing their positions, 58 reducing their positions, and 14 closing their positions.

New
Increased
Maintained
Reduced
Closed

329% more first-time investments, than exits

New positions opened: 60 | Existing positions closed: 14

50% more funds holding in top 10

Funds holding in top 10: 6 → 9 (+3)

23% more funds holding

Funds holding: 185 → 228 (+43)

16% more capital invested

Capital invested by funds: $2B → $2.31B (+$314M)

16% more repeat investments, than reductions

Existing positions increased: 67 | Existing positions reduced: 58

1.19% less ownership

Funds ownership: 110.21% → 109.01% (-1.2%)

38% less call options, than puts

Call options by funds: $3.79M | Put options by funds: $6.1M

Holders
228
Holders Change
+43
Holders Change %
+23.24%
% of All Funds
2.81%
Holding in Top 10
9
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+50%
% of All Funds
0.11%
New
60
Increased
67
Reduced
58
Closed
14
Calls
$3.79M
Puts
$6.1M
Net Calls
-$2.31M
Net Calls Change
-$3.85M

Top Buyers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
+$40.1M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$13.1M
3
IC
Ikarian Capital
Texas
+$12.6M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$11.1M
5
EP
Eversept Partners
New York
+$9.63M

Top Sellers

1
BG
Bellevue Group
Switzerland
-$65.9M
2
Fidelity Investments
Fidelity Investments
Massachusetts
-$31.6M
3
PCH
Polar Capital Holdings
United Kingdom
-$27.4M
4
DTC
Deep Track Capital
Connecticut
-$16.8M
5
EAM
Eventide Asset Management
Massachusetts
-$16.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
HFS
226
Hughes Financial Services
Virginia
$32 +$27 +1 New
PCH
227
Polar Capital Holdings
United Kingdom
– -$27.4M -1,008,163 Closed
Renaissance Technologies
228
Renaissance Technologies
New York
– -$3.22M -118,488 Closed
ATC
229
Argent Trust Co
Tennessee
– -$230K -8,481 Closed
A
230
AlphaQuest
New York
– -$218K -8,018 Closed
VFA
231
Values First Advisors
Tennessee
– -$210K -7,728 Closed
KAS
232
Kestra Advisory Services
Texas
– -$97.8K -3,600 Closed
AB
233
Amalgamated Bank
New York
– -$56K -2,058 Closed
Group One Trading
234
Group One Trading
Illinois
– -$20.4K -748 Closed
SSG
235
Summit Securities Group
New York
– -$12.3K -452 Closed
QL
236
Quarry LP
New York
– -$4.89K -180 Closed
SA
237
Strategic Advocates
Utah
– -$3.44K -130 Closed
BFS
238
Bare Financial Services
Pennsylvania
– -$2.15K -79 Closed
CWP
239
Concord Wealth Partners
Virginia
– -$217 -8 Closed
SIS
240
Strategic Investment Solutions
Illinois
– -$136 -5 Closed
C
241
Covestor
United Kingdom
– -$55 -2 -25%
6 7 8 9
10

CLDX Hedge Fund Activity: Q1 2026 in Review

228 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q1 2026, worth a combined $2.31B — up 16% from $2B a quarter earlier.

Buyers outnumbered sellers: 60 funds opened new CLDX positions and 14 closed out — a net gain of 46 holders — while 67 added to existing stakes and 58 trimmed.

The largest buyer was Point72 Asset Management, adding an estimated $40.1M. The largest seller was Bellevue Group, cutting an estimated $65.9M.

  • 228 institutional investors held Celldex Therapeutics (CLDX) as of Q1 2026, up from 185 in Q4 2025.
  • Funds reported $2.31B of Celldex Therapeutics stock for Q1 2026, up 16% quarter-over-quarter.
  • 60 funds opened new Celldex Therapeutics positions in Q1 2026 and 14 closed out, a net change of +46 holders.
  • The largest Celldex Therapeutics buyer in Q1 2026 was Point72 Asset Management, an estimated $40.1M added.
  • The largest Celldex Therapeutics seller in Q1 2026 was Bellevue Group, an estimated $65.9M sold.

Based on aggregated 13F filings for Q1 2026.